ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO198

Hepcidin, Iron Indices, and Bone Mineral Metabolism in Non-Dialysis CKD

Session Information

Category: Bone and Mineral Metabolism

  • 402 Bone and Mineral Metabolism: Clinical

Authors

  • Lee, Sung Woo, Eulji General Hospital, Seoul, Korea (the Republic of)
  • Sung, Su Ah, Eulji Medical Center, Seoul, Korea (the Republic of)
Background

There have been some small studies which have reported that intravenous iron replacement was associated with levels of bone mineral metabolism markers. Disordered bone mineral metabolisms are also well-known risk factors of erythropoietin (EPO) resistance. Hepcidin is a key peptide for the EPO resistance and iron metbolism. Although the intimate association between hepcidin, iron indices, and bone mineral metabolism was expected, particularly in non-dialysis chronic kidney disease (CKD) patients, it has been studied sparsely. Therefore, we performed this study.

Methods

We reviewed data of 2,238 patients from a large-scale multicenter prospective Korean study (2,011–2,016), and excluded 214 patients with missing data on markers and related-medications of iron and bone mineral metabolism, hemoglobin, blood pressure and causes of CKD. Multivariate linear regression analysis was used to identify the association between iron and bone mineral metabolism.

Results

The proportion of CKD stage 1-5 were 16.2%, 18.7%, 37.1%, 21.6%, and 6.4%, respectively. Per each 10% increase in transferrin saturation (TSAT), there was a 0.013 mmol/l decrease in phosphorus [95% confidence interval (CI) -0.021–-0.004; P = 0.003] and a 0.022 nmol/l increase in logarithmic 25-hydroxyvitamin D (Ln-25OHD) levels (95% CI 0.005–0.040; P = 0.019). A 1 pmol/l increase in Ln-ferritin was associated with a 0.080 ng/l decrease in Ln-intact parathyroid hormone (Ln-iPTH) (95% CI -0.122–-0.039; P <0.001). Meanwhile, beta (95% CI) per 1 unit increase in phosphorus, Ln-25OHD, and Ln-iPTH for the square root of the serum hepcidin were 0.594 (0.257–0.932; P= 0.001), -0.270 (-0.431–-0.108; P = 0.001), and 0.115 (0.004–0.226; P = 0.042), respectively. In subgroup analysis, the relationship between phosphorus, 25OHD, and hepcidin was strongest in the positive-inflammation group.

Conclusion

Increased TSAT was associated with decreased and increased phosphorus and 25OHD levels, respectively, while increased ferritin was associated with decreased iPTH levels. Increased phosphorus and iPTH and decreased 25OHD were independently associated with increased hepcidin levels.